Results 101 to 110 of about 27,755 (279)

GIP increases human adipocyte LPL expression through CREB and TORC2-mediated trans-activation of the LPL gene

Journal of Lipid Research, 2010
GIP (glucose-dependent insulinotropic polypeptide) is a gastrointestinal hormone that regulates pancreatic islet function. Additionally, emerging evidence suggests an important physiological role for GIP in the regulation of adipocyte metabolism.
Su-Jin Kim, Cuilan Nian, Christopher H.S. McIntosh   +2 more
doaj   +1 more source

Evaluation of a secondary care multidisciplinary clinic for adults with early‐onset type 2 diabetes at high risk in Leicester, Leicestershire and Rutland

Diabetic Medicine, EarlyView.
Abstract Background Clinical services for adults with early‐onset type 2 diabetes (EOT2D) are in urgent need of improvement. Methods We evaluated a multi‐disciplinary clinic for individuals with EOT2D at high risk (HbA1c >9%/triglyceride >20 mmol/L), providing 2–3 flexibly arranged consultations per individual between March 2024 and September 2025 ...
Jonathan Goldney, Malak Hamza, Priscilla Sarkar, Harriet Morgan, Nicole Green, James Ridgeway, Victoria Alabraba, Laura Willcocks, Krupali Chandracant, Kashmala Javed, Rhys O'Callaghan, Finley Turner, Samuel Seidu, Claire L. Meek, Melanie J. Davies   +14 more
wiley   +1 more source

The Body weight Reducing Effects of Tirzepatide in People with and without Type 2 Diabetes: A Review on Efficacy and Adverse Effects

Patient Preference and Adherence
Thomas Leth Jensen,1 Andreas Brønden,1 Kristian Karstoft,1,2 David Peick Sonne,1,2 Mikkel Bring Christensen1– 3 1Department of Clinical Pharmacology, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, DK-2400, Denmark; 2Department
Jensen TL, Brønden A, Karstoft K, Sonne DP, Christensen MB   +4 more
doaj  

Evaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double‐Blind Phase II Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim This study aimed to evaluate its safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in Chinese adults with T2DM and to preliminarily compare its efficacy and safety with semaglutide through multiple subcutaneous injections. Materials and Methods In this multicentre, randomised, placebo‐controlled and semaglutide‐positive‐
Ping Jin, Linong Ji, Yangqing Huang, Haifeng Ding, Daosheng Xie, Xiaohui Jiang, Xuemei Yuan, Zhao Cao, Haibin Zhang, Jiandong Yuan   +9 more
wiley   +1 more source

Pathogenesis of type 2 diabetes in Japan and East Asian populations: Basic and clinical explorations

Proceedings of the Japan Academy. Series B, Physical and Biological Sciences
It is now accepted that the pathogenesis of type 2 diabetes in East Asians including Japanese differs distinctly from that in Caucasians. Many non-obese individuals in Japan develop type 2 diabetes and present clinically with insufficient insulin ...
Yutaka SEINO, Yuji YAMAZAKI
doaj   +1 more source

Gip, an Intestinal Metabolic Hormone.

, 1986
Using an established radioimmunoassay for immunoreactive gastric inhibitory polypeptide (IR-GIP) the metabolic actions of gastric inhibitory polypeptide (GIP) were investigated.
Kwasowski, Piotr.
core  

Dual Glucagon and GLP‐1 Receptor Agonist Survodutide Improves Biomarkers of Beta‐Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This post hoc analysis evaluated the effect of survodutide on beta‐cell function, insulin sensitivity, and glucose biomarkers in two phase 2 trial populations. Materials and Methods Trial 1404‐0002 randomised 413 participants with type 2 diabetes on metformin to receive survodutide, placebo, or semaglutide over 16 weeks.
Elif I. Ekinci, Sandra González Maldonado, Anna Unseld, Jorge Arrubla Martinez, Anita M. Hennige, Corinna Schoelch   +5 more
wiley   +1 more source

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote, Toshimasa Yamauchi, Yasushi Fukushima, Yoji Takatsuka, Marie Kato, Shijia Yan, Takayoshi Inoue, Luiza Borowska, Martina Brueckmann, Wataru Ogawa, on behalf of the SYNCHRONIZE‐JP Trial Investigators   +10 more
wiley   +1 more source

Reappraisal of GIP pharmacology for metabolic diseases.

, 2016
Glucagon-like peptide-1 (GLP-1) analogs are considered the best current medicines for type 2 diabetes (T2D) and obesity due to their actions in lowering blood glucose and body weight.
Müller, T.D., Clemmensen, C., Tschöp, M.H., Perez-Tilve, D., Finan, B.   +4 more
core   +1 more source

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This Phase 1b, randomised, double‐blind clinical trial investigated the contribution of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin. Materials and Methods Participants were randomised to receive the long‐acting
Tim Heise, Eric Zijlstra, Andrea Mari, William C. Roell, Kieren J. Mather, Axel Haupt, Panagiotis Flevaris, Ran Liao, Laiyi Chua, Charles Harris, Edward J. Pratt   +10 more
wiley   +1 more source